FDA's Tissue Reference Group Recognizes Five New BioLab Holdings Amniotic Membrane Allografts as HCT/Ps

The unique amniotic membrane allograft aids in the covering and protection of wounds

PHOENIX , Aug. 28, 2025 /PRNewswire/ -- BioLab Holdings, Inc. announced today that five of its amniotic membrane allograft products have received recognition from the Food and Drug Administration's (FDA) Tissue Reference Group (TRG) as human cell, tissue, or cellular or tissue-based products (HCT/Ps). This designation will help streamline the reimbursement process for providers and further validate the clinical utility of these advanced wound care solutions.

"This recognition by the FDA's TRG is a significant milestone for BioLab Holdings," said BioLab CEO Jaime Leija . "It reinforces our commitment to our continuum of care and supports our mission to improve patient outcomes through advanced